What Makes Axogen (AXGN) an Investment Bet?

1 hour ago 3

Soumya Eswaran

Thu, April 2, 2026 astatine 8:32 AM CDT 3 min read

TimesSquare Capital Management, an equity concern absorption company, released its “U.S. Small Cap Growth Strategy” fourth-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The strategy returned 3.70% (gross) and 3.45% (net) successful the 4th fourth compared to a 1.22% instrumentality for the Russell 2000 Growth Index. In 2025, the strategy returned 6.91% (gross) and 5.85% (net) compared to 13.01% for the index. Global equity markets ended the 4th connected a affirmative note, with Europe leading, followed by Emerging Markets. In astir markets, ample caps outperformed tiny caps. The commercialized truce betwixt the United States and China was prolonged for an further year, but planetary geopolitical concerns, whether related to tariffs oregon not, persisted. Third-quarter GDP exceeded expectations, but user caution persists amid ongoing labor-market softening, influencing the Fed’s determination connected interest-rate cuts. Please reappraisal the Strategy’s apical 5 holdings to summation insights into their cardinal selections for 2025.

In its fourth-quarter 2025 capitalist letter, TimesSquare Capital U.S. Small Cap Growth Strategy highlighted stocks similar Axogen, Inc. (NASDAQ:AXGN). Axogen, Inc. (NASDAQ:AXGN) is simply a biotechnology and aesculapian services institution that develops and commercializes technologies for peripheral nervus regeneration and repair. On April 1, 2026, Axogen, Inc. (NASDAQ:AXGN) closed astatine $33.58 per share. One-month instrumentality of Axogen, Inc. (NASDAQ:AXGN) was 15.16%, and its shares gained 97.07% implicit the past 52 weeks. Axogen, Inc. (NASDAQ:AXGN) has a marketplace capitalization of $1.74 billion.

TimesSquare Capital U.S. Small Cap Growth Strategy stated the pursuing regarding Axogen, Inc. (NASDAQ:AXGN) successful its 4th fourth 2025 capitalist letter:

"Our preferences among Health Care stocks are those companies providing caller therapies for unmet needs that bid premium pricing, oregon specialized work providers. New to the strategy was Axogen, Inc. (NASDAQ:AXGN), which develops technologies for peripheral nervus regeneration and repair from injuries caused by trauma, chronic conditions, oregon surgical procedures. Its flagship product, Avance Nerve Graft, is simply a decellularized quality nervus allograft that preserves autochthonal nervus microarchitecture portion eliminating immune rejection risk. It is the lone FDA-approved implantable biologic nervus allograft connected the market."

10 Highest Paid Jobs and Occupations successful the US

Axogen, Inc. (NASDAQ:AXGN) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 26 hedge money portfolios held Axogen, Inc. (NASDAQ:AXGN) astatine the extremity of the 4th quarter, up from 20 successful the erstwhile quarter. In Q4 2025, Axogen, Inc. (NASDAQ:AXGN) generated gross of $59.9 million, up 21.3% year-over-year. While we admit the imaginable of Axogen, Inc. (NASDAQ:AXGN) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article